Near-complete recanalization of jugular vein and multiple dural sinus thromboses with warfarin in a case of antiphospholipid syndrome
Data nadesłania: 24-09-2018
Data ostatniej rewizji: 19-11-2018
Data akceptacji: 23-11-2018
Data publikacji online: 23-12-2018
Data publikacji: 23-12-2018
Reumatologia 2018;56(6):406-408
Antiphospholipid syndrome is a cause of arterial and venous thrombosis especially in the young adult population. Although dural sinus thrombosis is a relatively rare complication of antiphospholipid syndrome, it may be a cause of morbidity and mortality. Extension of thrombosis and involvement of deep venous structures are poor prognostic factors in patients with dural sinus thrombosis, but the rate of near-complete recanalization is not known in antiphospholipid syndrome-related dural sinus thrombosis. Herein, a case of antiphospholipid syndrome with multiple dural sinus, deep cerebral vein and internal jugular vein thromboses is presented with demonstrative imaging findings and near-complete recanalization after warfarin.
Yokus O, Albayrak M, Balcik OS, et al. Risk factors for thrombophilia in young patients presenting with thrombosis. Int J H Hematol 2009; 90: 583-590.
Ferro JM, Canhao P, Stam J, et al. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 2004; 35: 664-670.
Aguiar de Sousa D, Lucas Neto L, Canhao P, et al. Recanalization in cerebral venous thrombosis: a systematic review and meta-analysis. Stroke 2018. doi: 10.1161/STROKEAHA.118.022129 [Epub ahead of print].
Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in antiphospholipid antibody syndrome. N Engl J Med 1995; 332: 993-997.
Patel SI, Obeid H, Matti L, et al. Cerebral venous thrombosis: current and newer anticoagulant treatment options. Neurologist 2015; 20: 80-88.
Reynaud Q, Lega JC, Mismetti P, et al. Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev 2014; 13: 595-608.
Nojima J, Suehisa E, Akita N, et al. Risk of arterial thrombosis in patients with anticardiolipin antibodies and lupus anticoagulant. Br J Haematol 1997; 96: 447-450.
Andreoli L, Fredi M, Nalli C, et al. Clinical significance of IgA anti-cardiolipin and IgA anti-2glycoprotein I antibodies. Curr Rheumatol Rep 2013; 15: 343.
Devreese KM. Antiphospholipid antibodies: evaluation of the thrombotic risk. Thromb Res 2012; 130 (Suppl 1): S37-40.
Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133-1138.
Sciascia S, Lopez-Pedrera C, Cecchi I, et al. Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome. Rheumatology 2016; 55: 1726-1735.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Journals System - logo
Scroll to top